Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

15

Share

Download to read offline

Muscle relaxant pmr

Download to read offline

mr

Related Books

Free with a 30 day trial from Scribd

See all

Related Audiobooks

Free with a 30 day trial from Scribd

See all

Muscle relaxant pmr

  1. 1. MUSCLE RELAXANT DR MANOJ KUMAR SINGH 1st YR PG PHYSICAL MEDICINE AND REHABILITATION
  2. 2. Classification on basis of site of action and mechanism of action PERIPHERALLY ACTING • Neuromuscular blockers • Non depolarizing agents Isoquinoline derivatives steriod derivatives – Tubocurarine Pancuronu ium – Doxacurium Pipecuronium – Atracurium Rapacuronium – Metocurine Rocuronium – Mivacurium Vecuronium • Depolarizing agents – Suxamethonium (Succinylcholine) – Decamethonium
  3. 3. Depolarizing agents: Succinyle choline These drugs are structural analogue of acetylcholine . They either act as antagonists ( non depolarizing) OR agonist (depolarizing) These drugs are used to increase the safety of general anesthetics These are used parentrally
  4. 4. • B) Centrally acting (spasmolytic drugs) • Diazepam ( act through GABAA) receptors) • Baclofen (GABA B) receptors • Dantroline ( act directly by interfering release of calcium from sarcoplasmic reticulum) • Note: • these drugs are used to control spastic muscle tone as in epilesy ,multiple scelerosis ,cerebral palsy, stroke,
  5. 5. Mechanism of Sk. muscle contraction • Initiation of impulse • Release of acetylcholine • Activation of nicotinic receptor at motor end plate • Opening of ion channel, passage of Na+ , depolarization of end plate
  6. 6. MUSCLE RELAXANT ACTION • Neuromuscular blocking agents used in clinical practice interfere with this process. • Drugs, can block neuromuscular transmission/ or muscle contraction by acting
  7. 7. • Presynaptically: To inhibit acetylcholine synthesis or release (practically not used). As they may have whole body unspecific nicotinic as well as muscarinic effects • Postsynaptically: • To block the receptor activity. • To block ion channel at the end plate • Clinically these drugs are only used as an adjuvant to general anesthesia, (only when artificial respiration is available.) • They interfere with the post synaptic action of acetylcholine.
  8. 8. • Non depolarizing (majority): Act by blocking acetylcholine receptors. • In some cases (in higher doses), act by blocking ion channels. • Depolarizing: act as agonists at acetylcholine receptors
  9. 9. Mechanism of action (non depolarizing agents) • At low doses: • These drugs combine with nicotinic receptors and prevent acetylcholine binding.as they compete with acetycholine for receptor binding they are called competitive blockers • Thus prevent depolarization at end-plate. • Hence inhibit muscle contraction, relaxation of skeletal muscle occurs.
  10. 10. • At high doses • These drugs block ion channels of the end plate. • Leads to further weakening of the transmission and reduces the ability of Ach- esterase inhibitors to reverse the action.
  11. 11. PHARMACOKINETICS • Administered intravenously • Cross blood brain barrier poorly (they are poorly lipid soluble) • Some are not metabolized in liver, their action is terminated by redistribution, excreted slowly and excreted in urine unchanged (tubocurarine, mivacurium, metocurine). • They have limited volume of distribution as they are highly ionized.
  12. 12. • Atracurium is degraded spontaneously in plasma by ester hydrolysis ,it releases histamine and can produce a fall in blood pressure ,flushing and bronchoconstriction. is metabolized to laudanosine( which can provoke seizures),Cisatracurium with similar pharmacokinetics is more safer. • non depolarizers are excreted via kidney ,have long half life and duration of action than those which are excreted by liver.
  13. 13. • Some (vecuronium, rocuronium) are acetylated in liver.( there clearance can be prolonged in hepatic impairment) • Can also be excreted unchanged in bile. • They differ in onset, duration and recovery • Uses: as adjuvant to anesthesia during surgery. • Control of ventilation (Endotracheal intubation) • Treatment of convulsion
  14. 14. DEPOLARIZING AGENTS • DRUGS Suxamethonium ( succinylecholine) • Decamethonium • Mechanism of action: • These drugs act like acetylcholine but persist at the synapse at high concentration and for longer duration and constantly stimulate the receptor. • First, opening of the Na+ channel occurs resulting in depolarization, this leads to transient twitching of the muscle, continued binding of drugs make the receptor incapable to transmit the impulses, paralysis occurs. • The continued depolarization makes the receptor incapable of transmitting further impulses
  15. 15. • Therapeutic uses: • When rapid endotracheal intubations is required. • Electroconvulsive shock therapy. • Pharmacokinetics: • Administered intravenously. • Due to rapid inactivation by plasma cholinestrase, given by continued infusion
  16. 16. SUCCINYLECHOLINE • It causes paralysis of skeletal muscle. • Sequence of paralysis may be different from that of non depolarizing drugs but respiratory muscles are paralyzed last • Produces a transient twitching of skeletal muscle before causing block • It causes maintained depolarization at the end plate, which leads to a loss of electrical excitability. • It has shorter duration of action.
  17. 17. • It stimulate ganglion sympathetic and para sympathetic both. • In low dose it produces negative ionotropic and chronotropic effect • In high dose it produces positive ionotropic and chronotropic effect.
  18. 18. • It act like acetylcholine but diffuse slowly to the end plate and remain there for long enough that the depolarization causes loss of electrical excitability • If cholinestrase is inhibited ,it is possible for circulating acetylcholine to reach a level sufficient to cause depolarization block
  19. 19. ADVERSE EFFECTS • Bradycardia preventable by atropine. • Hyperkalemia in patients with trauma or burns • this may cause dysrhythmia or even cardiac arrest. • Increase intraocular pressure due to contracture of extra ocular muscles . • increase intragastric pressure which may lead to emesis and aspiration of gastric content.
  20. 20. • Malignant hyperthermia: rare inherited condition probably caused by a mutation of Ca++ release channel of sarcoplasmic reticulum, which results muscle spasm and dramatic rise in body temperature. (This is treated by cooling the body and administration of Dantrolene) • Prolonged paralysis: due to factors which reduce the activity of plasma cholinesterase • genetic variants as abnormal cholinesterase, its severe deficiency. • anti -cholinesterase drugs • neonates • liver disease
  21. 21. • DANTROLENE • It acts directly • It reduces skeletal muscle strength by interfering with excitation- contraction coupling into the muscle fiber, by inhibiting the release of activator calcium from the sarcoplasmic stores. • It is very useful in the treatment of malignant hyperthermia caused by depolarizing relaxants. • This drug can be administered orally as well as intravenously. Oral absorption is only one third. • Half life of the drug is 8-9 hours.
  22. 22. BACLOFEN • It acts through GABA B receptors • It causes hyper polarization by increased K+ conductance reducing calcium influx and reduces excitatory transmitter in brain as well as spinal cord • It also reduces pain by inhibitory substance P. in spinal cord • It is less sedative • It is rapidly and completely absorbed orally • It has a half life of 3- 4 hours • It may increases seizures in epileptics • It is also useful to prevent migraine
  23. 23. THANK YOU
  • ssuser77517d

    Sep. 20, 2019
  • BhaktiJain2

    May. 9, 2019
  • RidhamPatel14

    Feb. 24, 2019
  • AleenaAugustine2

    Apr. 21, 2018
  • HardikSharma57

    Feb. 5, 2018
  • ShakshiiNaithani

    Dec. 24, 2017
  • MalakBeshara

    Dec. 4, 2017
  • SharadThorve

    Sep. 14, 2017
  • 100003704456966

    May. 9, 2017
  • PARMARCHIRAG526

    Apr. 28, 2017
  • ruthmaglonzo

    Mar. 22, 2017
  • FaiqZuikarnain

    Mar. 17, 2017
  • SaloniShukla3

    Dec. 14, 2016
  • fathimawasia

    May. 25, 2016
  • KkanuPriya1

    Mar. 23, 2016

mr

Views

Total views

1,907

On Slideshare

0

From embeds

0

Number of embeds

13

Actions

Downloads

168

Shares

0

Comments

0

Likes

15

×